BDTX (Black Diamond Therapeutics, Inc.) Earnings per share for the last four quarters

Public company logo of Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond (BDTX) relies on an advanced MAP system that enables the identification of hidden tumor targets inaccessible to standard therapy methods. The primary growth driver will be the upcoming results from Phase I and II trials of its lung cancer drug, while the lack of revenue has already been priced in by investors. This daily price chart, featuring an EPS of -303.80, complements the data regarding the MasterKey platform for combating rare mutations.

BDTX blackdiamondtherapeutics.com Earnings per share for the last twelve months (02/11/2024 - 11/17/2026)

Black Diamond Therapeutics, Inc. - analytical breakdowns and key metrics (BDTX)

Fundamental valuation:Black Diamond Therapeutics (BDTX)
Signature product of Black Diamond Therapeutics

Effective delegation of oncology trials to external contractors while retaining IP rights provides Black Diamond (BDTX) with operational flexibility. This model directly impacts net income dynamics, which this indicator mathematically captures. The metric measures the rolling annual rate of change in earnings per share over twelve months, revealing the actual fundamental trend. By analyzing the current EPS TTM YoY growth rate, an investor can assess the impact of currency fluctuations on the business's final margins.

Competitor analysis for Black Diamond

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Tx CCCC|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc. - Earnings per share for the last 12 months|Karyopharm Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|aadibio.com - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corp. - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX